Challenges of drug development during the COVID-19
Post# of 148187
(Total Views: 708)
Posted On: 05/03/2020 2:15:46 AM
Challenges of drug development during the COVID-19
pandemic: key considerations for clinical trial designs (preprint -under review)
Peer Review Status:UNDER REVIEW
15 Apr 2020Submitted to British Journal of Clinical Pharmacology
16 Apr 2020Assigned to Editor
16 Apr 2020Submission Checks Completed
19 Apr 2020Reviewer(s) Assigned
Abstract:
SARS-CoV-2 may cause the rapid release of inflammatory cytokines resulting in ARDS and multiple organ failure. Antiinflammatory drugs can relieve this response. IL-6, CCR5 and JAK kinase are potential targets for relieving SARS-CoV-2 caused inflammation.
Tocilizumab (ACTEMRA ) is a recombinant human monoclonal antibody that specifically binds to soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibits inflammatory IL-6-mediated signal transduction.
CytoDyn’s humanized CCR5 antagonist leronlimab (PRO140) has applied for a phase II clinical trial for adult patients with mild to moderate respiratory disease aer infection with SARS-CoV-2.
The JAK kinase inhibitors
baricitinib and ruxolitinib can inhibit JAK-mediated inflammatory processes and are currently in clinical trials for COVID19 (see Table 1).
https://d197for5662m48.cloudfront.net/documen...deef4c.pdf
pandemic: key considerations for clinical trial designs (preprint -under review)
Peer Review Status:UNDER REVIEW
15 Apr 2020Submitted to British Journal of Clinical Pharmacology
16 Apr 2020Assigned to Editor
16 Apr 2020Submission Checks Completed
19 Apr 2020Reviewer(s) Assigned
Abstract:
SARS-CoV-2 may cause the rapid release of inflammatory cytokines resulting in ARDS and multiple organ failure. Antiinflammatory drugs can relieve this response. IL-6, CCR5 and JAK kinase are potential targets for relieving SARS-CoV-2 caused inflammation.
Tocilizumab (ACTEMRA ) is a recombinant human monoclonal antibody that specifically binds to soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibits inflammatory IL-6-mediated signal transduction.
CytoDyn’s humanized CCR5 antagonist leronlimab (PRO140) has applied for a phase II clinical trial for adult patients with mild to moderate respiratory disease aer infection with SARS-CoV-2.
The JAK kinase inhibitors
baricitinib and ruxolitinib can inhibit JAK-mediated inflammatory processes and are currently in clinical trials for COVID19 (see Table 1).
https://d197for5662m48.cloudfront.net/documen...deef4c.pdf
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼